Choice of antihypertensive monotherapy does not predict outcome

In the ALLHAT trial, cumulative event rates for the primary outcome (fatal coronary heart disease or nonfatal myocardial infarction) according to primary treatment with chlorthalidone, amlodipine, or lisinopril. Compared to chlorthalidone, there was no significant difference with amlodipine (relative risk 0.98) or lisinopril (relative risk 0.99 percent) at a mean of 4.9 years.